Clinical trial of recombinant human growth hormone on dwarfism in children with primary nephrotic syndrome
10.13699/j.cnki.1001-6821.2024.04.008
- VernacularTitle:重组人生长激素对原发性肾病综合征儿童矮小症患儿的临床研究
- Author:
Xiao-Hao HU
1
;
Ying-Jian CAI
;
Yong-Cun CHEN
;
Min WU
;
Lang-Hu CHEN
Author Information
1. 福建医科大学附属第二医院儿科,福建泉州 362000
- Keywords:
acetate prednisone tablet;
recombinant human growth hormone;
primary nephrotic syndrome;
childhood dwarfism;
insulin like growth factor 1
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(4):515-518
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and adverse drug reactions of recombinant human growth hormone on dwarfism in children with primary nephrotic syndrome.Methods Children with dwarfism in primary nephrotic syndrome were divided into control group and treatment group.Patients in control group were orally administered prednisone acetate tablets,with an initial dose of 2 mg·kg-1·d-1,at once,no more than 60 mg in a single day,and after a duration of 6 weeks of full dosage,the dosage was reduced by 2.5 mg every 2 weeks until the maintenance dose of 5-10 mg·d-1 was administered for 12 months.Patients in treatment group were injected subcutaneously with recombinant human growth hormone 0.15 U·kg-1 at 0.5 h before bedtime every night on the basis of control group for a period of 12 months.The levels of height,bone age,standard deviation fraction of height(HtSDS),insulin-like serum growth factor 1(IGF-1),insulin-like growth factor binding protein 3(IGFBP-3),and the incidence of adverse drug reactions were compared between the two groups.Results There were 63 cases in control group and 63 cases in treatment group.The height of the children in treatment group and control group after treatment were(146.48±6.76)and(138.62±4.95)cm;the HtSDS values were-1.72±0.18 and-1.97±0.20;the IGF-1 values were(158.86±18.24)and(113.14±15.88)ng·mL-1;IGFBP-3 values were(5.21±0.83)and(3.13±0.71)μg·mL-1,the differences were all statistically significant(all P＜0.05).The incidence of adverse drug reaction in treatment group and control group were 9.52％(6 cases/63 cases)and 3.17％(2 cases/63 cases),with no statistically significant difference(P＞0.05).Conclusion Recombinant human growth hormone has a definite clinical efficacy,high safety,and effective promotion of growth and development in the treatment of primary nephrotic syndrome in children with dwarfism.
